If accompanied by successful safety and tolerability data (expected in Q4 2021), these results have the potential to demonstrate the competitive advantage of PYC’s technology in an area of major unmet need - blinding eye diseases
Market waits for that information to be confirmed before comitting, it seems. Those researched in this stock, its sector and competition commit a little earlier than the broader market. It just results in a rerate development and held low until then, accommodating funding arrangements. The longer this is held low the more violent the break out.
all IMO
PYC Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)